These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A randomized trial of mesenchymal stem cells in multiple system atrophy. Lee PH; Lee JE; Kim HS; Song SK; Lee HS; Nam HS; Cheong JW; Jeong Y; Park HJ; Kim DJ; Nam CM; Lee JD; Kim HO; Sohn YH Ann Neurol; 2012 Jul; 72(1):32-40. PubMed ID: 22829267 [TBL] [Abstract][Full Text] [Related]
3. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Lee PH; Kim JW; Bang OY; Ahn YH; Joo IS; Huh K Clin Pharmacol Ther; 2008 May; 83(5):723-30. PubMed ID: 17898702 [TBL] [Abstract][Full Text] [Related]
4. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Staff NP; Madigan NN; Morris J; Jentoft M; Sorenson EJ; Butler G; Gastineau D; Dietz A; Windebank AJ Neurology; 2016 Nov; 87(21):2230-2234. PubMed ID: 27784774 [TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391 [TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy. Chung SJ; Lee TY; Lee YH; Baik K; Jung JH; Yoo HS; Shim CJ; Eom H; Hong JY; Kim DJ; Sohn YH; Lee PH Stem Cells Int; 2021; 2021():9886877. PubMed ID: 34712335 [TBL] [Abstract][Full Text] [Related]
7. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635 [TBL] [Abstract][Full Text] [Related]
8. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis. Harris VK; Vyshkina T; Sadiq SA Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and Efficacy of Intra-Arterial Administration of Mesenchymal Stem Cells in an Animal Model of Double Toxin-Induced Multiple System Atrophy. Na Kim H; Yeol Kim D; Hee Oh S; Sook Kim H; Suk Kim K; Hyu Lee P Stem Cells Transl Med; 2017 May; 6(5):1424-1433. PubMed ID: 28296268 [TBL] [Abstract][Full Text] [Related]
10. A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting Phase I human trials. Chen BK; Staff NP; Knight AM; Nesbitt JJ; Butler GW; Padley DJ; Parisi JE; Dietz AB; Windebank AJ Transfusion; 2015 May; 55(5):1013-20. PubMed ID: 25413276 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390 [TBL] [Abstract][Full Text] [Related]
12. Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial. Akhlaghpasand M; Tavanaei R; Hosseinpoor M; Yazdani KO; Soleimani A; Zoshk MY; Soleimani M; Chamanara M; Ghorbani M; Deylami M; Zali A; Heidari R; Oraee-Yazdani S Stem Cell Res Ther; 2024 Aug; 15(1):264. PubMed ID: 39183334 [TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. Harris VK; Stark J; Vyshkina T; Blackshear L; Joo G; Stefanova V; Sara G; Sadiq SA EBioMedicine; 2018 Mar; 29():23-30. PubMed ID: 29449193 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946 [TBL] [Abstract][Full Text] [Related]
15. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Geser F; Wenning GK; Seppi K; Stampfer-Kountchev M; Scherfler C; Sawires M; Frick C; Ndayisaba JP; Ulmer H; Pellecchia MT; Barone P; Kim HT; Hooker J; Quinn NP; Cardozo A; Tolosa E; Abele M; Klockgether T; Østergaard K; Dupont E; Schimke N; Eggert KM; Oertel W; Djaldetti R; Poewe W; Mov Disord; 2006 Feb; 21(2):179-86. PubMed ID: 16161136 [TBL] [Abstract][Full Text] [Related]
16. Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells. Dongmei H; Jing L; Mei X; Ling Z; Hongmin Y; Zhidong W; Li D; Zikuan G; Hengxiang W Cytotherapy; 2011 Sep; 13(8):913-7. PubMed ID: 21545234 [TBL] [Abstract][Full Text] [Related]
17. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. Hare JM; Fishman JE; Gerstenblith G; DiFede Velazquez DL; Zambrano JP; Suncion VY; Tracy M; Ghersin E; Johnston PV; Brinker JA; Breton E; Davis-Sproul J; Schulman IH; Byrnes J; Mendizabal AM; Lowery MH; Rouy D; Altman P; Wong Po Foo C; Ruiz P; Amador A; Da Silva J; McNiece IK; Heldman AW; George R; Lardo A JAMA; 2012 Dec; 308(22):2369-79. PubMed ID: 23117550 [TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS; Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636 [TBL] [Abstract][Full Text] [Related]
19. Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. Krismer F; Seppi K; Wenning GK; Papapetropoulos S; Abler V; Goebel G; Schocke M; Poewe W Parkinsonism Relat Disord; 2019 Jan; 58():23-27. PubMed ID: 30145124 [TBL] [Abstract][Full Text] [Related]
20. The safety profile of mesenchymal stem cell therapy administered through intrathecal injections for treating neurological disorders: a systematic review and meta-analysis of randomised controlled trials. Mesa Bedoya LE; Camacho Barbosa JC; López Quiceno L; Barrios Arroyave F; Halpert K; España Peña JA; Salazar Uribe JC Stem Cell Res Ther; 2024 May; 15(1):146. PubMed ID: 38764070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]